A strong body of science shows that C15:0 promotes cardiometabolic, immune and liver health, while a key C15:0 metabolite can support mental and cognitive health.
Why C15:0 is becoming the essential, essential fatty acid.
Numerous studies have shown that people with higher circulating C15:0 concentrations have a lower risk having or developing type 2 diabetes. These studies were performed by prestigious research teams around the world, including Sweden, England, Canada, and Asia. One study showed that pregnant women with higher circulating C15:0 concentrations had a lower risk of developing gestational diabetes.
These benefits are likely due to C15:0’s demonstrated ability in animal models to and positive associations in human studies with:
Multiple studies have shown that people with higher circulating C15:0 concentrations have a lower risk of having nonalcoholic fatty liver disease (NAFLD) and severe nonalcoholic steatohepatitis, including children. NAFLD now affects 1 in 3 people, including 1 in 10 children, globally. It has been hypothesized that nutritional C15:0 deficiencies may be driving the global pandemic of fatty liver disease.
C15:0’s liver health benefits may be due to its demonstrated ability in relevant models to and positive associations in human epidemiological studies with:
People with higher circulating C15:0 concentrations have lower inflammation. Additionally, a study evaluating a model of arthritis demonstrated that higher C15:0 concentrations in the serum and joint fluid was associated with a lower risk of joint degradation and osteoarthritis.
These benefits may be due to C15:0’s demonstrated ability to:
Dozens of large, prospective cohort studies have consistently shown that people with higher circulating C15:0 concentrations are less likely to develop heart disease, including coronary heart disease, first myocardial infarction, and heart failure.
These benefits may be due to C15:0’s demonstrated ability in relevant models to and positive associations in human epidemiological studies with:
People with higher circulating C15:0 levels have a lower risk of having a variety of cancer types, including breast, small lung cell, squamous cell, colorectal, pharyngolaryngeal, and hematological cancers. C15:0 has direct anticancer activities and phenotypes.
Specifically, C15:0:
C15:0 and its metabolite, pentadecanoylcarnitine (PDC), can cross the blood-brain barrier and have targeted cell-based activities that support brain, cognitive, mood and sleep health. People with higher circulating C15:0 concentrations are less likely to have anxiety and distress.
Demonstrated C15:0 and PDC activities include:
One study by Fonteh et al. showed that people with higher C15:0 in their cerebral spinal fluid were less likely to have Alzhiemer’s disease.
Join the movement to help increase awareness of C15:0 to improve global health.